| Drug ID: | Drug200 |
|---|---|
| Drug Name: | Teicoplanin |
| CID: | 133065662 |
| DrugBank ID: | DB06149 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT06818565, , NCT05914467, , NCT04003818, , NCT04370145, , NCT04341831, , NCT02018094, , NCT00428844, , NCT03020901, , NCT01815541, , NCT00925093, , NCT00024453, , NCT00430937, , NCT00462878, , NCT00454272, , NCT00719056, , NCT00368498 |
| Molecular Formula: | C88H97Cl2N9O33 |
| Molecular Weight: | 1879.7 g/mol |
| Isomeric SMILES: | CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[ |
| Synonyms: | Antibiotic 8327A; Targocid; TEICOPLANIN; Tecoplanina; Tecoplanine; Tecoplaninum; Teicoplanina; Teicoplanine; Teicoplaninum; Teichomycin |
| Phase 0: | 0 |
| Phase 1: | 2 |
| Phase 2: | 2 |
| Phase 3: | 2 |
| Phase 4: | 8 |
| Description: | Teicoplanin is a glycopeptide antibiotic. It is a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, termed teicoplanin A3-1, a fused ring structure to which two carbohydrates (mannose and N-acetylglucosamine) are attached. The major and minor components also contain a third carbohydrate moiety, ?-D-glucosamine, and differ only by the length and conformation of a side chain attached to it. [Wikipedia] |
Molecular Structure
No molecular structure data available
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1404 | 133065662 | Teicoplanin | None | -- | Severe acute respiratory syndrome coronavirus 2 | 34798775 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Enhanced loading dose of teicoplanin for three days is required to achieve a ta…
PMID: 34844858
Year: 2022
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Because of its lower risk of renal toxicity than vancomycin, teicoplanin is the preferred treatment for methicillin-resistant Staphyloc…
Clinical efficacy and safety in patients treated with teicoplanin with a target…
PMID: 32641110
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: A trough concentration (C(min)) >/=20 mug/mL of teicoplanin is recommended for the treatment of serious methicillin-resistant Staphylococ…
Clinical efficacy of teicoplanin in the treatment of bloodstream infection caus…
PMID: 31870587
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Empirical combination therapy with beta-lactams and glycopeptides is recommended for patients with presumed staphylococcal bloodstream infection (BSI…